Market Intelligence, Clinical Progress, and High-Purity Reagents for DDR & Synthetic Lethality Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PARP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PARP1 WT & Drug-Resistance Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW. |
View PARP1 Products |
| Gene Delivery | PARP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and synthetic lethality models. |
View PARP1 Products |
| Benchmark Ab | Anti-PARP1 Recombinant Antibody Research-grade positive control for Western, IF, and ELISA detection. |
View PARP1 Products |
| Validator | PARP1 siRNA Set For knockdown verification and specificity controls in cell-based assays. |
View PARP1 Products |
| Related Target A | PARP2 Essential for PARP1/2 selectivity profiling and off-target counter-screening. |
View PARP2 Products |
| Related Target B | BRCA2 Synthetic lethality pathway partner; critical for combination and biomarker studies. |
View BRCA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PARP1/2 Isoform Selectivity & Off-target Risk | Homolog panel proteins (PARP1, PARP2, PARP3) strictly verified by mass spec, High Purity (>95%) |
| Drug Resistance Mechanism Profiling | PARP1 WT & Clinically Relevant Mutant Proteins (Resistance Hotspots); Theoretical MW confirmed. |
| DNA-Dependent Catalytic & Trapping Assays | High-purity, Endotoxin-controlled PARP1 suitable for PARylation, NAD+ consumption, and DNA-trapping assays. |
| Synthetic Lethality Cell Model Generation | PARP1 Lentivirus Particles for stable integration and knockdown rescue experiments. |
| Assay Standardization & Controls | Endotoxin-controlled (<1EU/µg) proteins; validated siRNA for specificity; clinical benchmark antibodies included. |
Live PARP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The PARP inhibitor market is transitioning from first-generation dual PARP1/2 inhibitors toward next-generation selective therapeutics. Key functional domains—including the PADR1 zinc-binding, BRCT, and WGR domains (UniProt P09874)—are essential for DNA damage recognition and catalytic activity. Clinically relevant mutations such as rs3738708, rs1805409, and rs3219057 have been cataloged in patient populations, underscoring the need for mutant-selective profiling. Established drugs like Olaparib and Niraparib validated the synthetic lethality approach, but their hematologic toxicities (driven by PARP2 inhibition) have created a clear differentiation opportunity for PARP1-selective agents. The next wave of R&D targets pure PARP1 selectivity to eliminate toxicities, alongside novel strategies such as PROTAC degraders and combination regimens with ATR, WEE1, and immune checkpoint inhibitors to overcome acquired resistance in HRD+ tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Dual PARP1/2) | AstraZeneca, GSK, Clovis, Pfizer | Ovarian, Breast, Prostate, Pancreatic Cancer | Selectivity Assay (Need PARP1 vs PARP2 high-purity enzymes) |
| PARP1-Selective Inhibitor | AstraZeneca (AZD5305), Gilead, Merck, IMPACT Therapeutics | Solid Tumors (Hematology-sparing) | High-resolution Selectivity Panel (Need PARP2 for counter-screening) |
| PROTAC / Degrader | Kymera, Nurix, Arvinas, C4 Therapeutics | PARPi-Resistant Tumors | Target Engagement & Degradation Assay (Need full-length functional PARP1 and Lentivirus) |
| Combination Therapy | GSK, Pfizer, Bayer + PD-1/PD-L1, ATR inhibitors | Refractory Cancers (TNBC, mCRPC) | Synergy Validation (Need pathway-related antigens like BRCA1, ATM) |
Molecular Differentiation & Assay Strategy
To develop best-in-class drugs, critical molecular differentiation dimensions include:
- Subtype Selectivity (PARP1 vs PARP2): Needs >50-fold selectivity to avoid PARP2-driven hematological toxicity. Assay: Parallel IC50 determination using high-purity PARP1 and PARP2 recombinant proteins (SPR/BLI).
- Catalytic Inhibition vs. PARP Trapping: The trapping efficiency (locking PARP1 onto DNA) is a key determinant of cytotoxicity. Assay: DNA-binding competent PARP1 with EMSA or cellular foci formation.
- Resistance Mutant Coverage: Clinically observed mutations (e.g., Gly863 variants, Tyr907Cys) require next-generation compounds with maintained affinity. Assay: Mutant recombinant protein panel for cross-resistance screening.
- Synthetic Lethality Pathway Validation: BRCA1/2, ATM status influences drug sensitivity. Assay: Provide BRCA1/ATM proteins for biochemical interaction and phosphorylation studies.
TarMart's solution supports these strategies with HEK293-expressed recombinant proteins ( >95% purity, <1EU/µg endotoxin), mutant panels, Lentivirus for stable cell lines, and validated siRNA/antibodies for specificity controls.